Hims & Hers Third Quarter 2026 Earnings Call - HIMS & HERS HEALTH INC

Financial Performance:

• Total Q3 2026 revenue reached $890 million, representing 49% year-over-year growth and accelerating for the second consecutive quarter.
• Subscriber count grew 13% YoY to 2.8 million but declined sequentially by 100,000 due to strategic marketing pullbacks and international brand migrations.
• Domestic revenue grew 21% YoY to $657 million; International revenue surged >400% YoY to $233 million, driven by Eucalyptus integration.
• Adjusted EBITDA was $82 million (9% margin), a 37% increase QoQ, excluding $18 million in deferred revenue.
• Gross margins declined 7 points QoQ to 57%, primarily driven by lower-margin branded weight loss products in international markets.
• Cash flow from operations was $65 million, generating $26 million in free cash flow for the quarter; cash and investments stood at over $710 million.
• Operating cost ratios improved: Marketing at 28% of revenue (down 7 points), and operations/support at 12% (down 1 point).

Guidance and Future Outlook:

• Q4 2026 revenue guidance set at $875–$895 million (42–45% YoY growth).
• Full-year 2026 revenue guidance tightened to $3.13–$3.15 billion (33–34% YoY growth).
• Full-year 2026 adjusted EBITDA guidance maintained at $257–$277 million (9% margin midpoint), reflecting aggressive strategic investments.
• 2027 adjusted EBITDA guidance reduced to $257–$277 million to account for marketing spend in UK/Germany and weight loss membership deferrals.
• International revenue run rate expected to exceed $1 billion in 2027; current 2026 expectation raised to at least $650 million.
• Anticipates positive free cash flow for the full year 2026 and strong positioning for 2027.
• Q4 will see moderated domestic marketing spend and subscriber headwinds, with a focus on broadening weight loss assortment and reactivating marketing engines in Q1 2027.

Business Segments and Product Lines:

• Weight Loss/Metabolic Health: Deepening partnerships with Novo (Wegovy, Cagri-Sema preparation) and Lilly (Zepbound, ZepFound); preparing multi-month subscription models to improve adherence and pricing accessibility.
• International Expansion: Consolidating brands under "Hims and Hers" in the UK, Germany, and Australia; HERS launched in UK/Australia, HIMSS in Germany/Australia; leveraging 24-month head start in EU for US strategy.
• New Specialties: Launched injectable and oral Testosterone Replacement Therapy (TRT) including controlled substances; launched Peptides Plus offering later this month (semaglutide, glutathione, NAD+); plans to add BPC-157 and TB-500 upon regulatory clearance.
• Infrastructure: Operating >1 million sq. ft. of pharmacy, lab, and compounding facilities in the U.S., enabling in-house sterile compounding for peptides and TRT.

Market and Competitive Landscape:

• Strategy focuses on owning the customer relationship rather than transactional care, aiming to become the primary global health destination.
• Believes market economics improve as categories mature (comparing to sexual health and hair categories), driven by generic entry and price reductions.
• Canada cited as a precursor model where generic availability drove 50% growth in average monthly orders and margin expansion.
• Aiming to hold #1 or #2 market positions in key international markets by diversifying beyond weight loss into dermatology, sexual health, and hormonal balance.
• Differentiation via proprietary technology, direct customer access, and a unified AI-native care platform compared to competitors.

Risks and Challenges:

• Regulatory uncertainty surrounding peptide therapies (specifically TB-500 and BPC-157) and pending FDA rulemaking on enforcement discretion.
• Near-term subscriber growth volatility due to intentional marketing pullbacks and international brand consolidation.
• Short-term gross margin pressure from international scale and lower-margin branded weight loss mix.
• Dependency on successful execution of complex care models (e.g., TRT, peptides) requiring robust clinical infrastructure and compliance.
• Potential for "known knowns" in weight loss category pricing and assortment not yielding immediate subscriber returns before Q1 2027.

Management Commentary and Tone:

• Tone is confident and forward-looking, emphasizing a "multiplier model" where platform efficiencies and customer trust drive long-term value over short-term transaction volume.
• Management explicitly trades near-term subscriber growth for long-term market leadership, citing the decision to pause marketing spend as a strategic move to prepare for Q1 2027 demand.
• CEO Andrew Dudum reinforced the thesis that "whoever owns the customer relationship wins," highlighting the shift from single-transaction care to holistic, continuous health management.
• CFO Yemi Okupe emphasized disciplined capital allocation and the belief that current investments in technology and international scale will yield high leverage in the future.

Analyst Questions and Answers:

• Wearables: Plan is to integrate all major wearable data (universal integration) rather than restricting users; long-term strategy includes offering own devices at near cost to avoid data lock-ins and broaden monitoring.
• Peptides: Manufacturing of raw APIs (e.g., TB-500) will be in-house in Menlo Park to ensure quality; regulatory clarity expected in coming weeks; pricing expected to be integrated into membership for cross-category incentives.
• Subscriber Decline: Attributed to deliberate marketing pullback in weight loss and brand migrations; recovery expected in Q1 2027 driven by new Lilly/Novo assortment and seasonal demand.
• AI/Native Platform: AI-native experience now covers 70% of weight loss users; driving 4x message engagement and reducing non-clinical tasks; largest engineering hiring quarter focused on scaling this infrastructure.
• Gross Margins: Decline attributed to international mix; long-term outlook expects margin expansion via verticalization, generic adoption, and operational leverage similar to historical sexual health trends.

Other Key Points:

• Andrew Huberman joined the board and serves as a scientific advisor.
• 70% of weight loss subscribers accessed the AI-native experience by Q3 end; full rollout expected by year-end.
• Revenue exclusion of $18 million deferred from weight loss memberships impacts Q3 recognized revenue but not free cash flow.
• Platform now supports over 3 million people across four continents.
• Strategic focus on "category expansion" to keep the platform growing and sticky, moving beyond single-condition treatment to whole-of-life care.